These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 34429327)

  • 1. Translating the Science of Cancer Dormancy to the Clinic.
    Aguirre-Ghiso JA
    Cancer Res; 2021 Sep; 81(18):4673-4675. PubMed ID: 34429327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Dormancy and Relapse: From a Natural Byproduct of Evolution to a Disease State.
    Manjili MH
    Cancer Res; 2017 May; 77(10):2564-2569. PubMed ID: 28507050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy.
    Lian X; Yang K; Li R; Li M; Zuo J; Zheng B; Wang W; Wang P; Zhou S
    Mol Cancer; 2022 Jan; 21(1):27. PubMed ID: 35062950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pattern recognition of tumor dormancy and relapse beyond cell-intrinsic and cell-extrinsic pathways.
    Manjili MH; Khazaie K
    Semin Cancer Biol; 2022 Jan; 78():1-4. PubMed ID: 34990835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance.
    Sabaawy HE; Ryan BM; Khiabanian H; Pine SR
    Carcinogenesis; 2021 Dec; 42(12):1411-1419. PubMed ID: 34415330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of tumor microenvironment and exosomes in dormancy and relapse.
    Attaran S; Bissell MJ
    Semin Cancer Biol; 2022 Jan; 78():35-44. PubMed ID: 34757184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precision Cancer Trials With Immunomodulatory Agents: Personalizing Histology Agnostic Approaches.
    Baretti M; Azad NS
    Cancer J; 2019; 25(4):287-295. PubMed ID: 31335393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer evolution: Darwin and beyond.
    Vendramin R; Litchfield K; Swanton C
    EMBO J; 2021 Sep; 40(18):e108389. PubMed ID: 34459009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tackling cancer cell dormancy: Insights from immune models, and transplantation.
    Corthay A; Bakacs T; Thangavelu G; Anderson CC
    Semin Cancer Biol; 2022 Jan; 78():5-16. PubMed ID: 33582171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: Immune Cell Lineage Reprogramming in Cancer.
    Leavenworth JW; Shi LZ; Wang X; Wei H
    Front Immunol; 2021; 12():838464. PubMed ID: 35126385
    [No Abstract]   [Full Text] [Related]  

  • 11. Cellular dormancy in minimal residual disease following targeted therapy.
    Ruth JR; Pant DK; Pan TC; Seidel HE; Baksh SC; Keister BA; Singh R; Sterner CJ; Bakewell SJ; Moody SE; Belka GK; Chodosh LA
    Breast Cancer Res; 2021 Jun; 23(1):63. PubMed ID: 34088357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dual face of NAMPT: Intracellular/extracellular protein and diagnostic/therapeutic target in cancer.
    Audrito V
    EBioMedicine; 2020 Dec; 62():103109. PubMed ID: 33160209
    [No Abstract]   [Full Text] [Related]  

  • 13. Synthetic Lethal Networks for Precision Oncology: Promises and Pitfalls.
    Shen JP; Ideker T
    J Mol Biol; 2018 Sep; 430(18 Pt A):2900-2912. PubMed ID: 29932943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Techniques in Understanding Cancer Biology and Metabolism.
    Biswas D; Khan MW
    Technol Cancer Res Treat; 2020; 19():1533033820943248. PubMed ID: 32672097
    [No Abstract]   [Full Text] [Related]  

  • 15. Thorny ground, rocky soil: Tissue-specific mechanisms of tumor dormancy and relapse.
    Lim AR; Ghajar CM
    Semin Cancer Biol; 2022 Jan; 78():104-123. PubMed ID: 33979673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of exosomal lncRNAs in cancer biology and clinical management.
    Zhang W; Wang Q; Yang Y; Zhou S; Zhang P; Feng T
    Exp Mol Med; 2021 Nov; 53(11):1669-1673. PubMed ID: 34819615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crosstalk between autophagy and microbiota in cancer progression.
    Wang Y; Du J; Wu X; Abdelrehem A; Ren Y; Liu C; Zhou X; Wang S
    Mol Cancer; 2021 Dec; 20(1):163. PubMed ID: 34895252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Architecture of Cancer-Associated Fibroblasts in Tumor Microenvironment: Mapping Their Origins, Heterogeneity, and Role in Cancer Therapy Resistance.
    Dzobo K; Dandara C
    OMICS; 2020 Jun; 24(6):314-339. PubMed ID: 32496970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the Versatile Wnt/β-Catenin Pathway in Cancer Biology and Therapeutics: From Concept to Actionable Strategy.
    Dzobo K; Thomford NE; Senthebane DA
    OMICS; 2019 Nov; 23(11):517-538. PubMed ID: 31613700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.
    Walcher L; Kistenmacher AK; Suo H; Kitte R; Dluczek S; Strauß A; Blaudszun AR; Yevsa T; Fricke S; Kossatz-Boehlert U
    Front Immunol; 2020; 11():1280. PubMed ID: 32849491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.